PetroQuest Energy, Inc. (PQ) Analysts See $-0.06 EPS; Bio-path Holdings (BPTH) Sellers Increased By 32.51% Their Shorts

April 17, 2018 - By Darrin Black

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

Analysts expect PetroQuest Energy, Inc. (NYSE:PQ) to report $-0.06 EPS on May, 2.They anticipate $0.17 EPS change or 73.91% from last quarter’s $-0.23 EPS. After having $-0.02 EPS previously, PetroQuest Energy, Inc.’s analysts see 200.00% EPS growth. The stock increased 3.20% or $0.02 during the last trading session, reaching $0.52. About 5,251 shares traded. PetroQuest Energy, Inc. (NYSE:PQ) has declined 72.11% since April 17, 2017 and is downtrending. It has underperformed by 83.66% the S&P500.

Bio-path Holdings Inc (NASDAQ:BPTH) had an increase of 32.51% in short interest. BPTH’s SI was 225,400 shares in April as released by FINRA. Its up 32.51% from 170,100 shares previously. With 55,500 avg volume, 4 days are for Bio-path Holdings Inc (NASDAQ:BPTH)’s short sellers to cover BPTH’s short positions. The stock increased 1.20% or $0.02 during the last trading session, reaching $1.68. About 12,279 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 76.76% since April 17, 2017 and is downtrending. It has underperformed by 88.31% the S&P500.

PetroQuest Energy, Inc. operates as an independent gas and oil company. The company has market cap of $13.31 million. The firm is involved in the acquisition, exploration, and development of gas and oil properties in Texas and the Gulf Coast Basin. It currently has negative earnings. As of December 31, 2016, it had estimated proved reserves of 1.4 thousand barrels of oil, 26.6 billion cubic feet equivalent of natural gas liquids, and 81 billion cubic feet of natural gas.

Among 13 analysts covering Petroquest Energy Inc. (NYSE:PQ), 5 have Buy rating, 1 Sell and 7 Hold. Therefore 38% are positive. Petroquest Energy Inc. had 21 analyst reports since July 21, 2015 according to SRatingsIntel. Roth Capital maintained PetroQuest Energy, Inc. (NYSE:PQ) on Monday, August 14 with “Buy” rating. The stock of PetroQuest Energy, Inc. (NYSE:PQ) has “Sector Perform” rating given on Monday, December 14 by Howard Weil. The stock of PetroQuest Energy, Inc. (NYSE:PQ) earned “Equal-Weight” rating by Capital One on Thursday, August 4. The rating was upgraded by CapitalOne to “Overweight” on Monday, October 10. The stock of PetroQuest Energy, Inc. (NYSE:PQ) has “Buy” rating given on Friday, August 26 by Johnson Rice. The stock has “Buy” rating by Seaport Global on Wednesday, March 30. On Wednesday, June 21 the stock rating was maintained by Roth Capital with “Buy”. The stock has “Buy” rating by Roth Capital on Wednesday, May 31. Seaport Global downgraded PetroQuest Energy, Inc. (NYSE:PQ) on Wednesday, June 21 to “Neutral” rating. As per Tuesday, August 11, the company rating was upgraded by Zacks.

Investors sentiment increased to Infinity in Q4 2017. Its up Infinity, from 0 in 2017Q3. It increased, as 0 investors sold PetroQuest Energy, Inc. shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 16,000 shares or 73.73% less from 60,900 shares in 2017Q3 were reported. Pinnacle Limited Liability Corporation holds 2,500 shares. Paradigm Management Inc New York holds 0% or 13,500 shares.

Among 2 analysts covering Bio-Path Holdings (NASDAQ:BPTH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Path Holdings had 4 analyst reports since April 18, 2016 according to SRatingsIntel. H.C. Wainwright maintained the shares of BPTH in report on Friday, August 11 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, July 20. The company was maintained on Monday, November 13 by H.C. Wainwright. The company was initiated on Monday, April 18 by Rodman & Renshaw.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $19.05 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>